TUBERCULOSIS
AND THE
TUBERCLE BACILLUS
2ND EDITION
Cover images: Cording M. tuberculosis infected by fluorescent reporter phage φ2DRM9, courtesy of Paras Jain and Torin Weisbrod, Albert Einstein College of Medicine, Bronx, NY.

Copyright © 2018 by ASM Press. ASM Press is a registered trademark of the American Society for Microbiology. All rights reserved. No part of this publication may be reproduced or transmitted in whole or in part or reutilized in any form or by any means, electronic or mechanical, including photocopying and recording, or by any information storage and retrieval system, without permission in writing from the publisher.

Disclaimer: To the best of the publisher’s knowledge, this publication provides information concerning the subject matter covered that is accurate as of the date of publication. The publisher is not providing legal, medical, or other professional services. Any reference herein to any specific commercial products, procedures, or services by trade name, trademark, manufacturer, or otherwise does not constitute or imply endorsement, recommendation, or favored status by the American Society for Microbiology (ASM). The views and opinions of the author(s) expressed in this publication do not necessarily state or reflect those of ASM, and they shall not be used to advertise or endorse any product.

Library of Congress Cataloging-in-Publication Data

Names: Jacobs, William R., Jr., editor.

Title: Tuberculosis and the tubercle bacillus / edited by William R. Jacobs, Jr., Department of Immunology and Microbiology, Albert Einstein School of Medicine, Bronx, New York, Helen McShane, Cellular Immunology and Vaccine Development Group, Nuffield Department of Medicine, Jenner Institute, University of Oxford, Oxford, United Kingdom, Valerie Mizrahi, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Faculty of Health Sciences, Rondebosch, South Africa, Ian M. Orme, Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, Colorado.


Identifiers: LCCN 2017038089 (print) | LCCN 2017040375 (ebook) | ISBN 9781555819569 (ebook) | ISBN 9781555819552 (print)

Subjects: LCSH: Tuberculosis.

Classification: LCC QR201.T6 (ebook) | LCC QR201.T6 T83 2018 (print) | DDC 614.5/42--dc23

LC record available at https://lccn.loc.gov/2017038089

doi:10.1128/9781555819569

Printed in Canada

10 9 8 7 6 5 4 3 2 1

Address editorial correspondence to: ASM Press, 1752 N St., N.W., Washington, DC 20036-2904, USA.

Send orders to: ASM Press, P.O. Box 605, Herndon, VA 20172, USA.

Phone: 800-546-2416; 703-661-1593. Fax: 703-661-1501.

E-mail: books@asmusa.org

Online: http://www.asmscience.org
# Contents

**Contributors** ix  
**Preface** xiii  

## SECTION I

**TOWARDS EDWARD JENNER’S REVENGE: DEVELOPING AN EFFECTIVE TUBERCULOSIS VACCINE / 1**

### A. BASIC IMMUNOLOGY

1. Innate Immune Responses to Tuberculosis / 3  
   **Jeffrey S. Schorey and Larry S. Schlesinger**

2. Cytokines and Chemokines in *Mycobacterium tuberculosis* Infection / 33  
   **Racquel Domingo-Gonzalez, Oliver Prince, Andrea Cooper, and Shabaana Khader**

3. Regulation of Immunity to Tuberculosis / 73  
   **Susanna Brighenti and Diane J. Ordway**

4. The Memory Immune Response to Tuberculosis / 95  
   **Joanna R. Kirman, Marcela I. Henao-Tamayo, and Else Marie Agger**

5. Pathology of Tuberculosis: How the Pathology of Human Tuberculosis Informs and Directs Animal Models / 117  
   **Randall J. Basaraba and Robert L. Hunter**

### B. ANIMAL MODELS

6. Animal Models of Tuberculosis: An Overview / 131  
   **Ann Williams and Ian M. Orme**

7. Mouse and Guinea Pig Models of Tuberculosis / 143  
   **Ian M. Orme and Diane J. Ordway**

8. Non-Human Primate Models of Tuberculosis / 163  
   **Juliet C. Peña and Wen-Zhe Ho**

9. Experimental Infection Models of Tuberculosis in Domestic Livestock / 177  
   **Bryce M. Buddle, H. Martin Vordermeier, and R. Glyn Hewinson**

### C. VACCINES

10. Clinical Testing of Tuberculosis Vaccine Candidates / 193  
    **Mark Hatherill, Dereck Tait, and Helen McShane**

### D. HUMAN IMMUNOLOGY

11. Human Immunology of Tuberculosis / 213  
    **Thomas J. Scriba, Anna K. Coussens, and Helen A. Fletcher**
12 The Immune Interaction between HIV-1 Infection and Mycobacterium tuberculosis / 239
Elsa du Bruyn and Robert John Wilkinson

SECTION II

DRUG DISCOVERY AND DEVELOPMENT: STATE OF THE ART AND FUTURE DIRECTIONS / 269

13 Preclinical Efficacy Testing of New Drug Candidates / 271
Eric L. Nuermberger

14 Oxidative Phosphorylation as a Target Space for Tuberculosis: Success, Caution, and Future Directions / 295
Gregory M. Cook, Kiel Hards, Elyse Dunn, Adam Heikal, Yoshio Nakatani, Chris Greening, Dean C. Crick, Fabio L. Fontes, Kevin Pethe, Erik Hasenoehrl, and Michael Berney

15 Targeting Phenotypically Tolerant Mycobacterium tuberculosis / 317
Ben Gold and Carl Nathan

SECTION III

BIOMARKERS AND DIAGNOSTICS / 361

16 Tuberculosis Diagnostics: State of the Art and Future Directions / 363
Madhukar Pai, Mark P. Nicol, and Catharina C. Boehme

17 Latent Mycobacterium tuberculosis Infection and Interferon-Gamma Release Assays / 379
Madhukar Pai and Marcel Behr

18 Impact of the GeneXpert MTB/RIF Technology on Tuberculosis Control / 389
Wendy Susan Stevens, Lesley Scott, Lara Noble, Natasha Gous, and Keertan Dheda

SECTION IV

HOST AND STRAIN DIVERSITY / 411

19 The Role of Host Genetics (and Genomics) in Tuberculosis / 413
Vivek Naranbhai

20 The Evolutionary History, Demography, and Spread of the Mycobacterium tuberculosis Complex / 453
Maxime Barbier and Thierry Wirth

21 Impact of Genetic Diversity on the Biology of Mycobacterium tuberculosis Complex Strains / 475
Stefan Niemann, Matthias Merker, Thomas Kohl, and Philip Supply

22 Evolution of Mycobacterium tuberculosis: New Insights into Pathogenicity and Drug Resistance / 495
Eva C. Boritsch and Roland Brosch

SECTION V

THE SIGNATURE PROBLEM OF TUBERCULOSIS PERSISTENCE / 517

23 Acid-Fast Positive and Acid-Fast Negative Mycobacterium tuberculosis: The Koch Paradox / 519
Catherine Vilchèze and Laurent Kremer

24 Mycobacterial Biofilms: Revisiting Tuberculosis Bacilli in Extracellular Necrotizing Lesions / 533
Randall J. Basaraba and Anil K. Ojha

25 Killing Mycobacterium tuberculosis In Vitro: What Model Systems Can Teach Us / 541
Tracy L. Keiser and Georgiana E. Purdy

26 Epigenetic Phosphorylation Control of Mycobacterium tuberculosis Infection and Persistence / 557
Melissa Richard-Greenblatt and Yossef Av-Gay

27 DNA Replication in Mycobacterium tuberculosis / 581
Zanele Ditse, Meindert H. Lamers, and Digby F. Warner

28 The Sec Pathways and Exportomes of Mycobacterium tuberculosis / 607
Brittany K. Miller, Katelyn E. Zulauf, and Miriam Braunstein

29 The Role of ESX-1 in Mycobacterium tuberculosis Pathogenesis / 627
Ka-Wing Wong
30  The Minimal Unit of Infection: 
*Mycobacterium tuberculosis* in the 
Macrophage / 635  
Brian C. VanderVen, Lu Huang, 
Kyle H. Rohde, and David G. Russell

31  Metabolic Perspectives on Persistence / 653  
Travis E. Hartman, Zhe Wang, 
Robert S. Jansen, Susana Gardete, 
and Kyu Y. Rhee

32  Phenotypic Heterogeneity in *Mycobacterium* 
tuberculosis / 671  
Neeraj Dhar, John McKinney, and 
Giulia Manina

33  *Mycobacterium tuberculosis* in the Face of 
Host-Imposed Nutrient Limitation / 699  
Michael Berney and Linda Berney-Meyer

Index / 717
Contributors

Else Marie Agger
Department of Infectious Disease Immunology, Statens Serum Institut, Artillerivej 5, Copenhagen, Denmark

Yossef Av-Gay
Division of Infectious Diseases, Department of Medicine, University of British Columbia, Vancouver, Canada

Maxime Barbier
Laboratoire Biologie Intégrative des Populations, Evolution Moléculaire; Institut de Systématique, Evolution, Biodiversité, UMR-CNRS 7205, Muséum National d’Histoire Naturelle, Univ. Pierre et Marie Curie, EPHE, Sorbonne Universités, Paris, France

Randall J. Basaraba
Department of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado

Marcel Behr
McGill International TB Centre & Department of Epidemiology & Biostatistics, McGill University, Montreal, Canada

Michael Berney
Albert Einstein College of Medicine, Department of Microbiology and Immunology, New York, New York

Linda Berney-Meyer
Albert Einstein College of Medicine, Department of Microbiology and Immunology, New York, New York

Catharina C. Boehme
FIND, Geneva, Switzerland

Eva C. Boritsch
Institut Pasteur, Unit for Integrated Mycobacterial Pathogenomics, Paris, France

Miriam Braunstein
Department of Microbiology and Immunology, University of North Carolina – Chapel Hill, Chapel Hill, North Carolina

Susanna Brighenti
Center for Infectious Medicine (CIM), F59, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden

Roland Brosch
Institut Pasteur, Unit for Integrated Mycobacterial Pathogenomics, Paris, France

Bryce M. Buddle
AgResearch, Hopkirk Research Institute, Palmerston North, New Zealand

Gregory M. Cook
University of Otago, Department of Microbiology and Immunology, Otago School of Medical Sciences, Dunedin, New Zealand, and Maurice Wilkins Center for Molecular Biodiscovery, The University of Auckland, Auckland, New Zealand

Andrea Cooper
University of Leicester, Infection Immunity and Inflammation, Leicester, Leicestershire, United Kingdom

Anna K. Coussens
Clinical Infectious Diseases Research Initiative, Division of Medical Microbiology, Department of Pathology, and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa

Dean C. Crick
Colorado State University, Department of Microbiology, Immunology, and Pathology, Fort Collins, Colorado

Neeraj Dhar
Global Health Institute, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland

Keertan Dheda
Lung Infection and Immunity Unit, Division of Pulmonology and UCT Lung Institute, Department of Medicine, University of Cape Town, Cape Town, South Africa
Contributors

Zanele Ditse
MRC/NHLS/UCT Molecular Mycobacteriology Research Unit, DST/NRF Centre of Excellence for Biomedical TB Research, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa

Racquel Domingo-Gonzalez
Department of Molecular Microbiology, Washington University in St. Louis, St. Louis, Missouri

Elsa du Bruyn
Clinical Infectious Diseases Research Initiative, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Observatory, Republic of South Africa

Elyse Dunn
University of Otago, Department of Microbiology and Immunology, Otago School of Medical Sciences, Dunedin, New Zealand

Helen A. Fletcher
Immunology and Infection Department, London School of Hygiene & Tropical Medicine, London, United Kingdom

Fabio L. Fontes
Colorado State University, Department of Microbiology, Immunology, and Pathology, Fort Collins, Colorado

Susana Gardete
Department of Medicine, Division of Infectious Diseases, Weill Cornell Medical College, New York, New York

Ben Gold
Department of Microbiology and Immunology, Weill Cornell Medical College, New York, New York

Natasha Gous
Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand, National Health Laboratory Service and National Priority Program of the National Health Laboratory Service, Johannesburg, South Africa

Chris Greening
The Commonwealth Scientific and Industrial Research Organization, Land and Water Flagship, Acton, Australia, and Monash University, School of Biological Sciences, Clayton, Victoria, Australia

Kiel Hards
University of Otago, Department of Microbiology and Immunology, Otago School of Medical Sciences, Dunedin, New Zealand

Travis E. Hartman
Department of Medicine, Division of Infectious Diseases, Weill Cornell Medical College, New York, New York

Erik Hasenoehrl
Albert Einstein College of Medicine, Department of Microbiology and Immunology, Bronx, New York

Mark Hatherill
South African Tuberculosis Vaccine Initiative (SATVI) and Institute of Infectious Disease & Molecular Medicine (IDM), University of Cape Town, Wernher & Beit South Building, Anzio Road, Observatory, Cape Town, South Africa

Adam Heikal
University of Otago, Department of Microbiology and Immunology, Otago School of Medical Sciences, Dunedin, New Zealand, and Maurice Wilkins Center for Molecular Biodiscovery, The University of Auckland, Auckland, New Zealand

Marcela I. Henao-Tamayo
Department of Microbiology, Immunology and Pathology, Mycobacteria Research Laboratory, Colorado State University, Fort Collins, Colorado

R. Glyn Hewinson
Animal and Plant Health Agency – Weybridge, Addlestone, Surrey, United Kingdom

Wen-Zhe Ho
Animal Biosafety Level III Laboratory, Center for Animal Experiment, State Key Laboratory of Virology, Wuhan University, Wuhan, China; Department of Pathology and Laboratory Medicine, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania

Lu Huang
Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, New York

Robert L. Hunter
Department of Pathology and Laboratory Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas

Robert S. Jansen
Department of Medicine, Division of Infectious Diseases, Weill Cornell Medical College, New York, New York

Tracy L. Keiser
Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York

Shabaana Khader
Department of Molecular Microbiology, Washington University in St. Louis, St. Louis, Missouri

Joanna R. Kirman
Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand

Thomas Kohl
Molecular Mycobacteriology, Forschungszentrum Borstel, Leibniz-Zentrum für Medizin und Biowissenschaften, Borstel, Germany

Laurent Kremer
IRIM (ex-CPBS) UMR 9004, Infectious Disease Research Institute of Montpellier (IDRIM), Université de Montpellier, CNRS, Montpellier, France

Giulia Manina
Microbial Individuality and Infection Group, Institut Pasteur, 25 rue du Docteur Roux, Paris, France
Contributors

John McKinney
Global Health Institute, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland

Helen McShane
The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford, United Kingdom

Matthias Merker
Molecular Mycobacteriology, Forschungszentrum Borstel, Leibniz-Zentrum für Medizin und Biowissenschaften, Borstel, Germany

Brittany K. Miller
Department of Microbiology and Immunology, University of North Carolina – Chapel Hill, Chapel Hill, North Carolina

Yoshio Nakatani
University of Otago, Department of Microbiology and Immunology, Otago School of Medical Sciences, Dunedin, New Zealand, and Maurice Wilkins Center for Molecular Biodiscovery, The University of Auckland, Auckland, New Zealand

Vivek Naranbhai
Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom, and Centre for the AIDS Programme of Research in South Africa, University of KwaZulu Natal, Durban, South Africa

Carl Nathan
Department of Microbiology and Immunology, Weill Cornell Medical College, New York, New York

Mark P. Nicol
University of Cape Town, Cape Town, South Africa

Stefan Niemann
Molecular Mycobacteriology, Forschungszentrum Borstel, Leibniz-Zentrum für Medizin und Biowissenschaften, and German Center for Infection Research (DZIF), partner site Borstel, Borstel, Germany

Lara Noble
Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, Gauteng, South Africa

Eric L. Nuermberger
Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, and Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland

Anil K. Ojha
Wadsworth Center, NY State Department of Health and University at Albany, Albany, New York

Diane J. Ordway
Mycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado

Ian M. Orme
Colorado State University, Fort Collins, Colorado

Madhukar Pai
McGill International TB Centre & Department of Epidemiology & Biostatistics, McGill University, Montreal, Canada

Juliet C. Peña
Department of Pathology and Laboratory Medicine, Temple University Lewis Katz School of Medicine, 3500 N. Broad St., MERB 843, Philadelphia, Pennsylvania

Kevin Pethe
Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore

Oliver Prince
Department of Molecular Microbiology, Washington University in St. Louis, St. Louis, Missouri

Georgiana E. Purdy
Department of Microbiology and Immunology, Oregon Health Sciences University, Portland, Oregon

Kyu Y. Rhee
Department of Medicine and Department of Microbiology & Immunology, Division of Infectious Diseases, Weill Cornell Medical College, New York, New York

Melissa Richard-Greenblatt
Division of Infectious Diseases, Department of Medicine, University of British Columbia, Vancouver, Canada

Kyle H. Rohde
Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, Florida

David G. Russell
Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, New York

Larry S. Schlesinger
Department of Microbial Infection and Immunity, Center for Microbial Interface Biology, The Ohio State University, Columbus, Ohio

Jeffrey S. Schorey
Department of Biological Sciences, Eck Institute for Global Health, Center for Rare and Neglected Diseases, University of Notre Dame, Notre Dame, Indiana

Lesley Scott
Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, Gauteng, South Africa
Contributors

Thomas J. Scriba
South African Tuberculosis Vaccine Initiative, Division of Immunology, Department of Pathology, and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa

Wendy Susan Stevens
Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand, National Health Laboratory Service, and National Priority Program of the National Health Laboratory Service, Johannesburg, South Africa

Philip Supply
INSERM U1019; CNRS UMR 8204; Institut Pasteur de Lille, Center for Infection and Immunity of Lille; and Université Lille Nord de France, Lille, France

Derek Tait
Aeras, Blackriver Park, First Floor, Observatory, Cape Town, South Africa

Brian C. VanderVen
Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, New York

Catherine Vilchèze
Howard Hughes Medical Institute, Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York

H. Martin Vordermeier
Animal and Plant Health Agency – Weybridge, Addlestone, Surrey, United Kingdom

Zhe Wang
Department of Medicine, Division of Infectious Diseases, Weill Cornell Medical College, New York, New York

Digby F. Warner
MRC/NHLS/UCT Molecular Mycobacteriology Research Unit, Department of Pathology, and Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Rondebosch, South Africa

Robert John Wilkinson
Department of Medicine, Imperial College London, and The Francis Crick Institute Mill Hill Laboratory, London, United Kingdom

Ann Williams
Health UK, Porton Down, Salisbury, United Kingdom

Thierry Wirth
Laboratoire Biologie Intégrative des Populations, Evolution Moléculaire; Institut de Systématique, Evolution, Biodiversité, UMR-CNRS 7205, Muséum National d’Histoire Naturelle, Univ. Pierre et Marie Curie, EPHE, Sorbonne Universités, Paris, France

Ka-Wing Wong
Shanghai Public Health Clinical Center, Key Laboratory of Medical Molecular Virology, School of Basic Medical Sciences, Shanghai Medical College of Fudan University, Shanghai, People’s Republic of China

Katelyn E. Zulauf
Department of Microbiology and Immunology, University of North Carolina – Chapel Hill, Chapel Hill, North Carolina
It is the height of irony that the man who discovered the smallpox vaccine, Edward Jenner, lost both his wife and son to tuberculosis (TB). By the time smallpox was essentially eradicated, it is estimated that over 300 million people had died from this disease over the preceding century. Its eventual prevention—by a simple vaccine—clearly illustrates the power of scientific discovery and how its application can affect human health. Hundreds of millions of people have been spared death and suffering from infectious diseases because of the development of vaccines and chemotherapy agents in the last 100 years. Millions of lives have been saved with the use of the TB vaccine, BCG, and the development of chemotherapeutic regimens for TB. Depressingly, despite these effective interventions, TB remains one of the most challenging problems of global health, with over 9 million new cases and 1.6 million deaths each year. This crisis has been further compounded by the emergence of the HIV epidemic, as this explosive and deadly combination has dramatically increased the global spread of TB, including increasing numbers of cases of multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB.

Historically, mycobacterial disease has long been at the forefront of scientific discovery for infectious diseases. The leprosy bacillus, Mycobacterium leprae, the first bacterium to be associated with human disease, was initially visualized by Gerhard Armauer Hansen in 1873. Earlier, Jean Antoine Villemin was the first person to realize that lung tubercles were infectious and not cancerous. By the 1880s, Robert Koch, aware of both of these discoveries, not only observed the tubercle bacilli in tubercles, but developed a growth medium of heated serum to cultivate the tubercle bacillus outside of humans. He went on to repeat the transfer experiment of Villemin and transferred the disease of TB to numerous animal species, establishing the experimental paradigm (“the postulates”) of how to prove that an infectious agent is a cause of a disease. Koch’s findings led Albert Calmette and Camille Guérin to follow Jenner’s approach of developing an attenuated pathogen for use as a vaccine, using the bovine tubercle bacillus to develop the bacille Calmette-Guérin (BCG) vaccine that bears their names and is still used to this day.

It is noteworthy that Paul Ehrlich was sitting in the lecture hall when Robert Koch presented his work in 1882; he later went on to help Koch improve his staining techniques. By observing the selective staining of various cell types, including human cells and different bacteria, Ehrlich also developed the idea of chemotherapy—“magic bullets” that could kill microbial pathogens. He tried for years to develop a chemical that could kill the tubercle bacillus, with little success, though at the same time was far more successful in developing a treatment for syphilis. In the 1930s, his protégé Gerhard Domagk discovered the first sulfonamide to treat bacterial infections such as streptococcus, and as this fledging field expanded, para-amino salicylic acid and isoniazid were discovered to be active against the TB bacillus. Parallel studies by Salaman Waksman and Albert Schatz in the 1950s led to the discovery of streptomycin, the first bactericidal drug for the tubercle bacilli.

Despite these many historical advances, the TB bacillus—Mycobacterium tuberculosis—has proven to be a formidable adversary against numerous interventions. Nevertheless, despite the arduous challenges of
working with this dangerous pathogen, the field continues to persevere, and our continued success in the pursuit of knowledge would, we suspect, be applauded by Koch, Ehrlich, Calmette, and many others, as we strive to find and apply more effective cures for this dreadful disease. In this spirit, this textbook is a collection of state-of-the-art research aimed at understanding the TB bacillus, the way it infects its host, the mechanisms by which it persists in the face of host immunity, and current intervention and therapeutic methods. The contributors of this book believe that such continued and dedicated research efforts will eventually lead to better vaccines, better chemotherapies, and ultimately the eradication of TB—Edward Jenner’s revenge.

William R. Jacobs, Jr.
Helen McShane
Valerie Mizrahi
Ian M. Orme
Index

A
Acid-fast (AF) mycobacteria, 519, 528–529
AF-negative M. tuberculosis and cell wall alterations, 527–528
brief history of AF staining, 520–522
chemical structures of mycolic acids, 520
clinical diagnosis of TB, 522–523
importance of mycolic acids, 523–524
Koch paradox, 523
lipid accumulation, 526–527
loss of AF property, 526–527, 528
mycobacterial cell envelope, 523–526
non-mycolic acid-containing components, 524–526
process for loss of acid-fastness, 525
Acquired immunity, 35, 43
CD4 T cells in HIV-TB coinfection, 248–251
HIV-TB coinfection, 248–252
TB immune reconstitution inflammatory syndrome (TB-IRIS), 255–256
Adjunctive therapeutic vaccination, TB disease, 196–197
Animal models, 131, 139; see also
Experimental infection models;
Guinea pigs; Mouse models
assessment of new drugs, 136–137
assessment of vaccines, 135
cattle, 134
common experimental designs, 280
efficacy testing, 277–284
ethical and husbandry issues, 138–139
guinea pigs, 132
host response and pathogenesis, 134–135
limitations of, 137–139
mechanism of protection, 136
mice, 132, 279–280
mini pigs, 134
non-human primates (NHP), 132–133
pathology of tuberculosis, 117–121
primary host response to M. tuberculosis infection, 122–123
process and capacity, 135–136
rabbis, 133
rats, 133–134
Treg cell responses in experimental, 80–87
Treg cells in guinea pig model of TB, 85–86
Treg cells in mouse models of TB, 80–85
Treg cells in non-human primate models of TB, 86–87
tuberculosis disease progression in, 122
vaccine testing protocols, 136, 137
zebrafish, 133, 685, 686
Antibiotics, 535
Antibiotics treatment, extracellular M. tuberculosis in, 535
Antibiotic tolerance, 596
Antibodies
BCG vaccination and, 220
M. tuberculosis infection, 219–220, 221
role in anti-M. tuberculosis infection, 219
tuberculosis, 225–226
Antigen-presenting cells (APCs)
development of memory T cells, 98
function of, 74, 75
Antiretroviral therapy (ART), 389
HIV, 239
HIV-TB coinfection, 250
HIV-TB immune constitution inflammatory syndrome (IRIS), 252–253, 255–256
influence on T cell responses in coinfection, 251
Apoptosis, 563
Archaebacteria, 455
Archivel Farma SL, 202
Arginine auxotrophs, 702
Aristotle, 413
Asparagine auxotrophs, 702
Aspartate auxotrophs, 702
Association of Internal Medicine, 520
AstraZeneca, 282
ATP synthesis, 308–309
Auramine O, staining of M. tuberculosis, 522–523, 526–527
Austin, Robert, 597
Autophagy, 8, 10

717
Drosophila melanogaster, 17
Drug development clinical trials, 272–273
macaque models for evaluation, 170–171
targeting replicosome for new, 595–596
Drug-resistant *M. tuberculosis* strains evolution of, 502–508
 evolution of MDR-TB, 503, 506
 evolution of resistance to second-line drugs, 506–507
impact of GeneXpert MTB/RIF, 401, 402–404
microevolution during TB infection, 507–508
resistance to first-line drugs, 504
resistance to second-line drugs, 505
suggested model for genetic diversity of subpopulations, 507
Drug susceptibility testing (DST), 363
commercial liquid culture-based DST, 366–367
genotypic tests for, 367
line probe assays for resistance detection, 367–368
noncommercial methods, 367
phenotypic tests for, 366
pipeline of diagnostics, 370
Drug targets, menaquinone biosynthesis, 322–325, 329–346
class II persisters, 322–325, 329–346
population of nonreplicating, 322–325, 329–346
Dual-active molecules, 331–332
canonical and noncanonical targets of, 334

E
Ebola virus, 454
Efficacy, see Preclinical efficacy testing
Ehrlich, P., 520
Electron flow, 521
*Enterococcus faecalis*, 535, 536, 537, 538
Erdman strain, 170
*M. tuberculosis*, 166, 167, 168, 170, 171–172
*Escherichia coli*, 12, 309, 321, 464, 467, 535, 536, 557, 583, 590, 599, 610, 638, 662, 673, 676, 701
ESX-1 (ESAT-6 secretion system-1), 627, 631–632
damage of *M. tuberculosis*-containing phagosome, 628–630
innate immune mechanisms, 631
interventions by target, 631
phagosome disruption by, 628
regulations of, 630–631
role in TB pathogenesis, 630
Ethambutol
drug resistance, 502, 503, 504
tolerance of infected cells, 640
Ethical issues, animal models, 138–139
Ethionamide, drug resistance, 505
*Eubacteria*, 455
Evolution of MTBC animal-related *M. tuberculosis* complex (MTBC) strains, 461
biogeographical structure of
*M. tuberculosis* Beijing lineage, 463
correspondence table of strains by typing methods, 457
diagram of proposed evolutionary pathway, 456
fingerpint era, 454–455
genome-based phylogeny of MTBC, 459
global phylogeny of MTBC isolates, 465
global picture, 458–461
history and early (mis)conceptions, 453–454
limitations, 466–467
multiocus era, 455–458
pattern for evolving populations, 466
pregenomic era, 454–458
relativity of clock, 464–467
spoligotyping, 453, 457, 461
substitution rate estimates, 464–466
taxonomic nomenclature, 464
whole-genome phylogeny of strains of MTBC, 460
zooming into lineages, 461–464
Evolution of Mycobacterium tuberculosis drug-resistant strains, 502–503
 global spread of *M. tuberculosis* L2
Beijing and L4 strains, 499–500
L2 Beijing sublineage, 500–501
L4 sublineage, 501–502
lessons from *M. canetti*, 496–498
molecular key events in evolution, 497
neighbor-joining phylogeny scheme, 499
professional pathogenicity, 498–502
Expanded Program on Immunization (EPI), 193
World Health Organization, 193
Experimental infection models cattle, 177–178
deer, 179
goats, 178–179
Experimental medicine controlled human challenge models, 205
examples of, 205
potential outcomes in studies, 204–205
preclinical studies in, 205–206
product development and, 204
role in TB vaccine development, 203–206
scientific community, 206
Extensively drug-resistant (XDR) strains, 533

F
Fatty acids, *M. tuberculosis* in macrophages, 644–645
Fauci, Anthony, 117
Flow cytometry, 682–684, 685
Fluorescence-activated cell sorting (FACS), 683
Fluorescence recovery after photobleaching (FRAP), 678, 684
Foam cell formation, human post-primary TB, 125
Folate (vitamin B9), 707
Foxp3 (transcription factor forkhead box P3) coexpression with CD25, 74, 75–76, 78–79
function of, 73
host defense against *M. tuberculosis*, 82
Francisella tularenis, 609, 699, 709
revisiting heritability in post-GWAS era, 416
TB susceptibility, 413, 418–419, 427
Genomics, see Genetics and genomics
Genotype, 671
GlaxoSmithKline, 199
Global TB epidemic, 389–390
Glutamate auxotroph, 705–706
Glutamine synthetase (GS), 705
Goats, experimental infection of, 177, 178–179
Gordonia otitidis, 498
Granulocyte-macrophage colony-stimulating factor (GM-CSF), 144
Granulocytes, M. tuberculosis infection, 14–16
Granulomas
development, 680–681, 684, 687
guinea pig model, 152
in vitro models, 549–550
lung of human with primary tuberculosis, 118, 120–121
morphological features of, 533
M. tuberculosis infection, 217, 636
progressive caseating, 126
restricting M. tuberculosis movement, 35–36
term, 16
Granulomatous inflammation, 123
Guinea pigs, 150–153; see also Animal models
animal model, 132
anti-TB treatment, 86
BCG vaccination, 86
devices for aerosol exposure, 147
gating host cells from lung, 153
granulomas in lungs, 118, 124, 126
human-to-guinea pig transmission, 153
immunopathology of, 152
magnetic resonance imaging of infected lungs, 155
preclinical efficacy models, 282
response to infection, 123, 124, 154
TB disease progression, 122
Treg cells in, 80, 85–86
vaccines, 153–154
H
H37Rv strain of Mycobacterium tuberculosis, 166, 167, 168, 170, 172, 215
Harvard School of Public Health, 467
Helicobacter pylori, 462, 464, 594
Heritability, see Genetics and genomics
Heterogeneity, see Phenotypic heterogeneity
Histidine auxotroph, 703
HIV-1 (human immunodeficiency virus type 1)
functional impairment of CD4 T cells, 250–251
heritability at site of M. tuberculosis disease, 247
immunity to TB, 50
infected people, 239
interferons and, 39
mediating immunosuppression, 239–241
M. tuberculosis infection risk, 172, 475
replication at site of M. tuberculosis disease, 245–247
tuberculosis epidemic and, 389
tuberculosis resurgence, 222
HIV-TB-associated immune reconstitution inflammatory syndrome (IRIS)
acquired immunity and TB-IRIS, 255–256
hypercytokinemia in TB-IRIS, 233, 253
innate immunity and TB-IRIS, 252–253
model of innate receptor signaling in TB-IRIS, 254
HIV-TB coinfection
acquired immunity, 248–252
CD4 T cells in, 248–251
Cytotoxic lymphocytes in, 251–252
dendritic cells in, 244
dissemination and mycobacteremia in, 248
immune activation in, 247–248
immune reconstitution inflammatory syndrome (IRIS), 252–256
macrophages in, 241–243
natural killer (NK) cells in, 244–245
neutrophils in, 243–244
spectrum of disease in, 240
Hollow fiber systems diagram, 276
tuberculosis (TB) model, 275–277
Homeostatic regulation, 73
Homo sapiens
M. tuberculosis, 653
tuberculosis in, 453–454, 458, 460–462, 467
Host genetic studies, tuberculosis, 429
Host-mimicking platforms, 685–686
Host-pathogen coevolution, 428
Host-response, application of animal models, 134–135
Human immunology of tuberculosis
acquisition of M. tuberculosis infection, 213, 215–221
adaptive responses and spectrum of infection, 217–220
alveolar macrophages, 215–216
antibody responses, 219–220, 221
B cells, 217, 219–220
biomarkers in human TB, 226–227
granuloma, 2178
immunity to M. tuberculosis, 213
innate T cells, 216–217
neutrophils, 216
progression from infection to TB disease, 222–226
spectrum of pulmonary TB lesions, 218
stages of response to infection, 214
T cells, 217–218
Human models
challenge models, 205
in vitro, 345–346
Human tuberculosis (TB)
balance of Treg activity, 77
cavity formation in lungs, 119, 120
CD3+ T cell subsets in, 77–78
granuloma in lung, 118, 120–121
in vitro expansion of mycobacteria-specific Treg cells, 76–77
novel TB vaccine candidate MVA85A, 77–78
post-primary lung refection, 124–125
TB disease progression, 122
Treg at site of infection, 79–80
Treg cell responses in, 74–80
Treg cells and anti-TB treatment, 78–79
Treg cells and clinical *M. tuberculosis* strains, 78
Treg-mediated manipulation of immune cell activation, 73–79
Treg responses in cell and fluid samples, 79–80
Treg responses in tissue, 79
Husbandry issues, animal models, 138–139
Hypercytokinemia, TB-immune reconstitution inflammatory syndrome (TB-IRIS), 233, 235
Hypoxia, 341
redox homeostasis during, 307–308
relationship to metronidazole activity, 318
screening, 341, 342

I
Imidazopyridine amide, TB drug, 300, 305
Immune response, see Memory immune response

Immunity, see also Regulation of TB immunity
cytokines and chemokines in, 33–34
HIV infection and TB, 50
interleukin-6 (IL-6), 40–41
working model of, 42, 45
Immunodeficient mice, 145
Immunopathology, guinea pig model, 152
Immunosuppression, HIV-1 mediating, 239–241
Immunotherapy, vaccine development, 197
Inactivated whole-cell and fragmented TB vaccines, 202
Infectious Diseases Research Institute, 199
Inflammation, TB progression, 224–225
Infliximab, 36
Innate immunity, 16–17, 35, 106–107
HIV-TB coinfection, 214, 220, 221, 225
latent TB infection, 381–385
reducing test variability with, 385

Interferons (IFN-γ)
*M. tuberculosis* infection, 37–40
protection against TB, 102–104
roles in TB, 35
type I, 39–40
type II IFN-γ, 38–39

Interleukin-12 (IL-12) cytokine family, 42–45
IL-12, 43–44
IL-23, 44
IL-27, 44–45
IL-35, 45

Interleukin-17 (IL-17) cytokine family, 41–42
IL-17, 45–46
IL-22, 46

Interleukin-6 (IL-6) cytokine, 40–41
tables in *M. tuberculosis* (TB), 35
International Tuberculosis Host Genetics Consortium (ITHGC), 413, 416, 428
Intracellular receptors, *M. tuberculosis* infection, 10

In vitro models
granuloma models, 549–550
human, 545–546
investigating MTB infection, 548–550
mouse, 542–544
non-human primate (NHP), 544–545
zebrafish, 550

IPEX syndrome (immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome), 73, 74
Isocitrate lyase (Icl), *M. tuberculosis* in macrophages, 644, 645–647
Isoleucine auxotroph, 704

Isoniazid, 86
animal models for testing, 278–280
drug candidate, 272, 274
drug resistance, 503, 504, 505, 506
guinea pigs, 282
latency TB infection, 285–286
line probe assays for detecting resistance, 367–368
Treg cells in macaques, 86–87
tolerance of infected cells, 639–641
isoniazid preventive therapy (IPT), HIV, 239

Jeafreys, Sir Alec, 455
Johannesen, Wilhelm, 671

K
Kanamycin, drug resistance, 503, 505
Kaplan-Heilman analysis, vaccine, 138
Kinyoun, J., 521–522
Koch, Robert, 224, 390, 520
Koch paradox, 519, 523
Koch phenomena, 126

L
Laënnec, Rene, 121
Lamers, Meinert H., 581–599
Lansoprazole, TB drug, 300, 305
Latency, definition, 654
Latent TB infection (LTBl), 217, 226, 227, 239, 379, 385–386
human model, 593–594
IGRAs, 381–385
immunological principles underlying IGRA, 382
modeling chemotherapy of, 284–286
mouse model and clinical guidelines, 285
new skin tests, 385
purified protein derivative (PPD)-based TST, 381
testing methods for, 380

Leishmania, 146
Leishmanoid cells, 239
Leucine auxotroph, 704
Levofloxacin, drug candidate, 272–273

Line probe assays (LPAs)
detecting resistance to anti-TB drugs, 367–368
detecting resistance to second-line anti-TB drugs, 368–369

Linezolid
drug candidate, 272, 279
non-human primates, 283
Lipidomics, 683–684
Lipid synthesis, 332–334
Lipoarabinomannan (LAM)
improving detection, 369
rapid urine test, 366

Liqueur culture, TB diagnostics, 364
Listeria monocytogenes, 102, 203, 609, 611, 699, 709
Little, Clarence, 143
Loop-mediated amplification test, 365–366
Low oxygen recovery assay (LORA), 323
Lung, 3–6
cellular components, 4–5
*M. tuberculosis* interaction with, 6–16
mucus and surfactant, 5
pathology of C3HeB/FeJ mice, 281
post-primary reinfection, 124–125
post-primary TB in human, 125–127
schematic of, 4
soluble components in surfactant hypophase, 5–6
spectrum of human pulmonary TB lesions, 218

Lung macrophages, 4–5
cell death, 11
release of exosomes, 10–11
Lymphotactin (XCL1), 144
Lysine auxotroph, 703–704

M
Macaca fascicularis (cynomolgus macaque), 163, 172
Macaca mulatta (rhesus macaque), 163, 173
Macaque models
Golden Age of TB research, 163, 165
historical use of, 163–165
*M. tuberculosis*isam immunodeficiency virus coinfection, 171–172
TB drug evaluation, 170–171
TB pathogenesis study, 171
TB vaccine evaluation, 167, 170
treg cells in macaques, 86–87
validation of, 163
Macrophages, see also Mycobacterium tuberculosis in macrophage; *Mycobacterium tuberculosis* macrophage biology
basic principles of macrophage biology, 546–548
cell death, 11
exosome release from, 10–11
HIV-TB coinfection, 241–243
human in vitro models, 545–546
lung, 4–5
mouse in vitro models, 542–544
*M. tuberculosis* and, 541–542
*M. tuberculosis* growth in, 700–701
Macrophages (Continued)
mycobacterial growth and HIV-1 viral replication, 243
non-human primate in vitro models, 544–545
Magnetic resonance imaging (MRI), infected guinea pig lungs, 153
Major histocompatibility complex (MHC), 38, 39, 49, 74, 97
Malnutrition, 223–224
Marmosets (Callithrix jacchus), 172, 284
McMaster (Ad5Ag85A), 201
Memory immune response against tuberculosis (TB), 96–97
alternative mediators of memory immunity, 105–107
CD4T and Th1 cells, 104–105
CD4T and T helper (Th) 1 cells, 95–96, 102–104
CDB T cells, 105–106
development after TB infection or vaccination, 98
γδ T cells, 106
generation of memory T cells, 97–99
innate memory, 106–107
memory T cell heterogeneity, 99–102
models of T cell fate, 98–99
natural killer (NK) cell memory, 107
novel TB vaccines, 107–108
resident memory T cells, 101–102
stem cell-like memory T cells, 102
T cell memory and TB vaccination, 107–108
T cell memory phenotypes, 100
trained immunity in monocytes, 107
Memory T cells, 95
CDB, 105–106
development after infection or vaccination, 98
enzyme-linked immunospot (ELISPOT) method, 182
generation of, 97–99
innate memory, 98–99
models of fate, 98–99
phenotypes, 100
proposed models of differentiation, 99
resident, 101–102
stem cell-like, 102
TB vaccination and, 107–108
vaccine efficacy, 182
Menaquinone biosynthesis, 302–303, 304
Mendelian susceptibility to mycobacterial disease (MSMD), 413, 415, 416, 417
Merck Research Laboratories, 596
Metabolomics, 683–684, 700–701
Methionine auxotrophs, 702–703
Methyl citrate cycle, M. tuberculosis in macrophages, 644, 645–647
Metronidazole, 278
hypoxia and activity of, 318
mice, 279, 286
non-human primates, 283
proof-of-concept molecule, 333
rabbits, 283
Microbiology, explorative tools and methodologies, 682–686
Micrococcus luteus, 611
Microfluidics, 684–685
MicroRNAs (miRNAs), 10
Microscopy, time-lapse, 684–685
Millennium Development Goals, 389
Minimal unit of infection, 635, 648
Mini pigs, animal model, 134
Modified Henderson apparatus, 167, 173
Monocytes trained immunity in, 107
tuberculosis, 224–225
Moorella, 458
Morbidity, impact of GeneXpert MTB/ RIF, 400
Mortality, impact of GeneXpert MTB/RIF, 400–401
Mouse models, 143–150, 278–280; see also Animal models
animal model, 132, 137
anti-TB treatment, 85
C3HeB/FeJ mice, 280–281
clinical M. tuberculosis strains, 83
common experimental designs, 280
Cornell model, 284–286
devices for aerosol exposure, 147
experimental infection of mice, 279–280
gene-disrupted mice, 144–145
genetic studies in mice, 145–146
immunodeficient, transgenic and congenic mice, 145
innate immunity, 145
in vitro, 542–544
latent TB infection (LTBI), 285
low-dose aerosol exposure to M. tuberculosis, 148
lung inflammatory response, 147
mouse response to infection, 146–150
obstructive alveolar pneumonia, 126
persistence in M. tuberculosis infection, 654–655, 657–659
preclinical efficacy models, 278–281
proposed regulation T cell suppression, 84
TB disease progression, 122
Treg cells and TB vaccination, 83–84
Treg cells in, 80–83
Treg cells in chronic TB infection, 82–83
Treg cells in early TB infection, 81–82
Moxifloxacin
animal model, 279
drug candidate, 272, 331
drug resistance, 305
guinea pigs, 282
proof-of-concept molecule, 333
Mucosal associated invariant T (MAIT) cells, 5
M. tuberculosis infection, 216–217, 549
Multidrug-resistant (MDR) strains, 533
Mutagenesis, M. tuberculosis, 595
MVA85A (modified vaccinia Ankara virus expressing antigen 85A)
testing protocols, 136
trial in South Africa, 137–138, 153–154
Mycobacteria
C-family DNA polymerases, 586, 588–591
DNA synthesis, 334–335, 336
evaluating bactericidal action against nonreplicating, 329
fluoroquinolones, 339
folate synthesis, 338
high-throughput screens targeting phenotypically tolerant, 322–323, 325
4-hydroxyquinolines, 338, 339
8-hydroxyquinolines, 338, 339
lipid synthesis, 332–334, 336
membrane depolarizers, 343–346
metabolism and respiration, 309–310
oxidative phosphorylation, 295
peptidoglycan synthesis, 335, 337, 338
persistence and resistance, 597–599
population heterogeneity as function of applied stress, 598
protein synthesis, 335, 337
proteolyis/proteostasis pathway, 339–341
quinolines, 338–339
replication machinery, 383, 386
respiration, 309–310
RNA synthesis, 335, 336
screening, 341–343
strategies for evaluating nonreplicating, 323
targeting oxygen reduction in, 303, 305–308
Mycobacterial biofilms, 533, 535, 536
extracellular M. tuberculosis in necrotizing lesions, 535–536
formation, 535, 536, 537
Mycobacterial replisome, working model of, 582
Mycobacteria orygis, 460
Mycobacteria other than tuberculosis (MOTT), 495
Mycobacteriology, 460, 467
Mycobacterium africanum, 453, 455–460, 477
Mycobacterium avium, 13, 52, 679
Mycobacterium bovis, 476, 477
bovine tuberculosis (TB), 177
Ravenel strain, 133
Mycobacterium bovis bacille Calmette-Guérin (BCG), 6, 12, 13, 15, 703
BCG vaccine-induced protection, 43, 46
C3HeB/FeJ mice, 281
cattle model, 134
expansions of Teg cells, 76
responses of innate immune cells to, 12
vaccine, 95, 117, 179–180, 627
Mycobacterium canettii, 456, 458, 460, 476, 477, 479, 481–483, 485
drug resistance, 502
lessons to learn from, 496–498
Mycobacterium caprae, 460, 461, 476, 477, 479, 496
Mycobacterium flavescens, 382
Mycobacterium haemophilum, 495
Mycobacterium kansasii, 382, 495
Mycobacterium leprae, 382, 428, 495, 709
replisome components, 584–586, 587
Mycobacterium lepromatosis, 495
Mycobacterium marinum, 14, 382, 495, 679
mycolic acids, 523
virulence, 610
zebrafish model, 36, 133, 699
Mycobacterium mungi, 461, 496
Mycobacterium orygis, 460, 476, 479, 496, 498
Mycobacterium phlei, 6, 295
Mycobacterium pinnipedii, 460, 461, 476, 477, 479
Mycobacterium prototuberculosis, 458
Mycobacterium smegmatis, 458
Mycobacterium szulgai, 382
Mycobacterium tuberculosis, 3; see also HIV-TB coinfection

ATP synthesis by F1F0 ATP synthase, biological differences between animal and

biological differences between M. canettii and, 482
biological impact of genetic diversity, 480
evidence for potential of biological variation, 480–481
global emergence of multidrug-resistant TB strains, 475–477
global genetic diversity, 477–484
global phylogenetic structure of MTBC strains, 476
global phylogeny of MTBC isolates, 465
intrapatient diversity, 479–480

Mycobacterium tuberculosis infection, see also Protein phosphorylation
apoptosis, 563
cell wall remodeling, 569–570
defense against host-generated reactive oxygen and nitrogen species, 563–564
growth arrest, 567–569

Mycobacterium tuberculosis in macrophage bottleneck response, 637
chemical genetics of infection, 634–644
cholesterol, 645, 646
construction of reporter strains, 638–639, 640
drug sensitivity of, 641
environmental cues and responses, 638
fatty acids, 644–645
flow cytometry gating strategy, 642
flow sorting strategy, 641

Neisseria meningitidis, 197
Neutrophils
HIV-TB coinfection, 243–244
lung, 5
M. tuberculosis infection, 12, 39, 216, 548
response to M. tuberculosis, 125

Nicolosamide, 343–344, 346
Nicotinamide, 706
Nigericin, 297, 298
Nile red stain, 526–527

M. tuberculosis in macrophage

Nocardia farcinica, 3

Nile red stain, 526–527
Nitro-containing compounds, dual- and

Niclosamide, 343–344, 346
Nocardia farcinica, 3

Non-human primate models, see also Animal models
animal model, 132–133
comparison of rhesus and cynomolgus
macaque models, 165–167
cynomolgus macaques, 166–167, 169
future research strategies, 172
historical use of macaque models, 163–165

in vitro, 544–545
macaque models for study of TB
pathogenesis, 171
macaque models for TB drug evaluation, 170–171
macaque models for TB vaccine evaluation, 167, 170

M. tuberculosis/simian immunodeficiency
virus coinfection, macaque models, 171–172

Mycobacterium ulcerans, 495
Mycobacterium vaccae, 197

Mycolic acids
chemical structures of, 520
importance of, 523–524
loss of acid-fastness, 519, 529
Myxococcus xanthus, 673

N
NADH-ubiquinone oxidoreductases, 299–300
National Institute for Health and Care Excellence (UK), 379
National Institute of Allergy and Infectious Diseases, 117
National Primate Research Centers (NPRCs), 164, 165, 166, 170, 171, 172
National TB Costing Model, 395, 398
Natural killer (NK) cells
HIV-TB coinfection, 244–245
memory, 107
M. tuberculosis infection, 12–14
Natural resistance-associated macrophage protein (Nramp), 146
Neanderthals, 467
Necrosis-associated extracellular clusters (NECs), 151, 153

Neisseria meningitidis, 197
Neutrophils
HIV-TB coinfection, 243–244
lung, 5
M. tuberculosis infection, 12, 39, 216, 548
response to M. tuberculosis, 125

Niclosamide, 343–344, 346
Nicotinamide, 706
Nigericin, 297, 298
Nile red stain, 526–527
Nitro-containing compounds, dual- and
nonreplicating active, 343, 344
3-Nitropropionate, 300, 301
Nocardia farcinica, 13
Nongrowing but metabollically active
bacteria (NGMA), 676
identification of, 678, 681, 683

Non-human primate models, see also Animal models
animal model, 132–133
comparison of rhesus and cynomolgus
macaque models, 165–167
cynomolgus macaques, 166–167, 169
future research strategies, 172
historical use of macaque models, 163–165

in vitro, 544–545
macaque models for study of TB
pathogenesis, 171
macaque models for TB drug evaluation, 170–171
macaque models for TB vaccine evaluation, 167, 170

M. tuberculosis/simian immunodeficiency
virus coinfection, macaque models, 171–172

Mycobacterium orygis, 460, 476, 479, 496, 498
Mycobacterium phlei, 6, 295
Mycobacterium pinnipedii, 460, 461, 476, 477, 479
Mycobacterium prototuberculosis, 458
Mycobacterium smegmatis, 458
Mycobacterium szulgai, 382
Mycobacterium tuberculosis, 3; see also HIV-TB coinfection

ATP synthesis by F1F0 ATP synthase, biological differences between animal and
Non-human primate models (Continued)
preclinical efficacy models, 283–284
rhesus macaques, 165, 166, 168
Treg cells in, 80, 86–87
validation of macaques in TB
research, 163
Nonreplicating (NR) models, selecting and
designing, 323, 324
Nonreplicating persistence (NRP)
M. tuberculosis physiology for, 567–571
sensing when to exit NRP, 571–572
Nonreplication, diversity in, 319–321
Nontuberculous mycobacteria (NTM), 495
Nucleic acid amplification testing (NAAT),
495
O
Ofloxacin, drug resistance, 505
Oxidative phosphorylation
growth reactivation, 301–302
M. tuberculosis, 295
P
Paiäbo, Svante, 467
Paleomicrobiology, 467
PAMP (pathogen-associated molecular
pattern), 467
Pantothenate (vitamin B5), 706
Paradigm, 121
Parkinson diseases, 630
Pathogenesis
application of animal models, 134–135
macaque models for studying TB, 171
persisting, 672
Pathogens, see Nutrient use of pathogens
Pathology of tuberculosis, 117–121,
125–127
alveolar pneumonia, 126
cavity formation, 119, 120
disease progression in animal models, 122
granuloma within the lung, 118
hypersensitivity of pathogenesis of post-
primary TB, 123–125
intrapulmonary spread of mixed
inflammatory cells, 121
lipid pneumonia, 121, 125
obstructive lobular pneumonia, 121, 123
post-primary lung reinfection, 124–125
primary host response to M. tuberculosis
infection, 122–123
Pattern recognition, 145
Penicillin, 317–318
Peripheral blood mononuclear cells
(PBMCs), 4
Peroxisome proliferator-associated receptor
gamma (PPARγ), 4, 10
Persistence
definition, 654
drug-induced, 662
gene deletion studies, 659–661
host-induced, 657–662
measurements, 656–662
messages, 662–663
methods, 656
models, 654–656
pathogenicity of M. tuberculosis, 653, 672
physiology of M. tuberculosis, 653
predicted genes for in vivo survival of
M. tuberculosis, 661
terms, 653–654
Persisters, 317
class I, 321–322
class II, 322–325, 329–346
diversity in nonreplicating cells, 319–321
killing class II persisters, 329, 331–341
Phagocytosis, 636
Phagosome maturation, 8, 9
Phenotype, 671
Phenotype definitions, 429
Phenotypically tolerant M. tuberculosis,
317–319
class I persisters, 321–322
class II persisters, 322–325, 329–346
compound transformation during
screening and secondary assays,
325, 329
conditions for replication rates of, 326
designing high-throughput screens to
target, 322–325
diversity in nonreplication, 319–321
evaluating bactericidal action against
nonreplicating mycobacteria, 329
fluoroquinolones, 339
future studies, 347–348
high-throughput screening (HTS),
341–343
key observations, 319
key recommendations, 348
killing class II persisters, 329, 331–341
membrane depolarizers, 343–346
modelling hypoxia and metronidazole
activity relationship, 318
molecules targeting nonreplicating
mycobacteria, 346, 347
nitro-containing compounds, 343
postscreening assays, 327, 328
proof-of-concept molecules, 331–332
proteolysis/prooestasis pathway,
339–341
quinolines and derivatives, 338–339
screening assays, 325, 329, 330
selecting and designing nonreplicating
models, 324
strategies for evaluating viability of
nonreplicating, 323
Phenotypic drug resistance, 317
Phenotypic heterogeneity, 671–672
asymmetric cell division and cell aging,
676–679
causes and consequences of, 673
flow cytometry andomics, 682–684
fluorescence recovery after photobleaching
(FRAP), 678, 684
growth phase, 674–675
growth rate, 675–676
host microenvironment, 679–682
host-mimicking platforms, 683–686
in vivo investigation, 685–686
stochastic processes, 672–674
stress conditions enhancing, 677
time-lapse microscopy and microfluidics,
684–685
tools and methodology, 682–686
Phenotypic tolerance, 317
Phosphorylation, see Protein
Phosphorylation
Pneumonia, tuberculosis as obstructive
lobular, 121, 123
Positron emission tomography/computed
tomography (PET/CT), 171, 213,
283, 680–681, 686
Post-primary tuberculosis, 124–125
Preclinical efficacy testing, 271, 274
animal infection models of active TB,
277–284
drug candidates, 272–273
dynamic drug concentration models,
275–277
goals of, 274–275
guinea pigs, 282
hollow fiber system model of TB, 275–277
in vitro models, 275–277
mice, 278–281
modeling chemotherapy of latent TB
infection (LTBI), 284–286
non-human primates, 283–284
rabbits, 283
rats, 281–282
static drug concentration models, 275
Preclinical studies, role in experimental
medicine studies, 205–206
Pretomanid
drug candidate, 273
guinea pigs, 282
mice, 279
Prime, vaccine development, 197
Prime-boost, vaccine development, 197
Programmed cell death protein-1 (PD-1),
101–102
Proline auxotroph, 703
Proof-of-concept molecules
dual actives with in vivo efficacy, 331–332
nonreplicating actives with in vivo efficacy, 332
nonreplicating activity, 333
selective nonreplicating activity, 331
Protein-adjuvant TB vaccines, 198–200
Protein kinase activity, 557
Protein phosphorylation, see also
Mycobacterium tuberculosis infection
apoptosis, 563
biochemically verified substrates of
M. tuberculosis serine/threonine
protein kinases (STPKs), 358–359
effect on M. tuberculosis STPKs, 566
growth and persistence phenotypes of
M. tuberculosis STPKs, 562
hierarchy of M. tuberculosis STPK
activation, 561
inhibition of phagosomal-lyosome fusion,
561, 563
M. tuberculosis, 557, 559–560
STPKs coordinating M. tuberculosis
physiology, 567–571
STPKs regulating M. tuberculosis
morphology, 564–565, 567
Proteomics, 679, 683–684
Proton motive force (PMF), 297
mechanisms, 297
targeting, in M. tuberculosis, 295–299
traditional inhibitors of PMF
generation, 298
Pseudomonas, 673
Pseudomonas aeruginosa, 13, 321, 467, 536, 591, 594
Pseudomonas putida, 591
Pseudomicrocardia dioxanivorans, 498
PubChem, 329
Puromycin, 681
Pyrazinamide, 86
Pyrizinamide, 86
Pyridoxamine (vitamin B6), 706–707
Purine auxotroph, 708
PubChem, 329, 498
Pseudonocardia dioxanivorans, 591
Pseudomonas putida, 591
Pseudomonas aeruginosa, 13, 321, 467, 536, 591, 594
Pseudomonas putida, 591
Pseudomicrocardia dioxanivorans, 498
Purine auxotroph, 681
drug resistance, 502, 504
proof-of-concept molecule, 333
tolerance of infected cells, 640
Pyridoxamine (vitamin B6), 706–707

R
Rats
animal model, 133
granulomas in lungs, 126
preclinical efficacy models, 283
response to infection, 123, 124
TB disease progression, 122
Rapid speciation strip tests, 364
Ritaprine
animal model, 133–134
preclinical efficacy models, 281–282
Recombinant mycobacterial vaccines, 202–203
Regulation of TB immunity, see also Animal models; Human tuberculosis (TB) antigen-presenting cells (APCs), 74, 75
human regulatory T (Treg) cells and anti-TB treatment, 78–79
human Treg cells and clinical M. tuberculosis strains, 78
in vitro expansion of mycobacteria-specific Treg cells, 76–77
mechanisms of Treg suppression, 74
naturally occurring and induced Treg cells, 73–74
Treg activity balance, 77
Treg cell, 73–74
Treg cell responses in experimental animal models of TB, 80–87
Treg cell responses in human TB, 74–80
Treg-mediated manipulation of immune cell activation, 75–79
Treg responses at M. tuberculosis infection site, 79–80
Treg suppression of APCs, 75
Regulatory cytokines
IL-4, IL-5, and IL-13, 47–48
interleukin IL-10, 48–49
transforming growth factor β (TGFβ), 48
Replication rate, 592; see also DNA replication
mycobacterial, 592–594
Research Institute of Influenza
(St. Petersburg, Russia), 202
Respiration, M. tuberculosis, 295
Restriction fragment length polymorphism (RFLP) method, 454–455, 583
Retroviridae family, 239
Rhesus macaques, 163; see also Macaque models
comparing TB in humans to, 164
“Golden Age” of TB research using, 163, 166
Macaca mulatta, 163, 173
TB studies, 166, 167, 168
21st century TB research, 166
Rhizobium leguminosarum, 613
Rifampin, 86, 527–528
animal models, 279–280
drug candidate, 272, 274, 278, 331
drug resistance, 503, 504, 674
guinea pigs, 282
latent TB infection, 285–286
line probe assays for detecting resistance, 367–368
non-human primates, 283
proof-of-concept molecule, 333
tolerance of infected cells, 639–641
Xpert MTB/RIF for resistance to, 368
Rifapentine
drug candidate, 272
guinea pigs, 282
latent TB infection (LTBI), 285–286
Salmonella
Salmonella enterica
S. enterica serovar Typhi, 462
Salmonella typhimurium, 557
Sanofi Pasteur, 199
Scavenger receptors (SRs), 8
ScFv
Screening
acidic pH, 341, 342
biofilms, 341, 343
hypoxia, 341, 342
multiple physiological stresses, 341, 342
Screening assays
compound transformation during, 330
designing high-throughput screens for phenotypically tolerant mycobacteria, 322–323, 325
post-, 327, 328
potential compound transformation during, 325, 329
Secretion (SecA1) pathway
cell wall synthesis and remodeling factors, 609
conserved, 607–608
conserved SecA1 exportome, 608–611
entering dormancy, 610
exported virulence factors, 610
lipoproteins, 609–610
models of SecA1 export, 608
reactivation/resuscitation from dormancy, 611
Secretion (SecA2) pathway
dormancy, 619
features of SecA2-dependent substrates, 613
identification, 611–612
immunomodulation and, 618–619
inhibition of apoptosis, 618
KatB (catalase-peroxidase), 616
Mce transporters, 614–615
mechanism, 612–613
models of SecA2 export, 608
multiple components of Mce transporters, 615
phagosome maturation arrest, 617
PknG (eukaryotic-like serine-threonine kinase), 616
protein export pathway, 611–613
reactive radicals and, 619
SBPs (solute binding proteins), 613–614
secA2 mutant as vaccine candidate, 619–620
SecA2 and DosR regulon, 616–617
SecA2 exportome, 613–616
SodA (Fe-superoxide dismutase), 615–616
virulence and, 617–619
Secretion system, see also ESX-1 (ESAT-6 secretion system–1)
ESAT-6 (ESX-1), 627, 631–632
Shuman, Stewart, 591
Simian immunodeficiency virus (SIV), M. tuberculosis and, coinfection
macaque models, 171–172
Smear microscopy, diagnostics for active TB, 363–364
Solute carrier, 146
South Africa
challenges and opportunities of implementation, 394, 396
GeneXpert implementation, 397
GeneXpert placement, 394
national implementation of Xpert NTB/RIF assay, 393–394
tuberculosis in, 391, 393
South African Tuberculosis Vaccine Initiative (SATVI), 104, 105
Spectroscopy, 683–684, 701
Spoligotyping, 455, 457, 461
Staphylococcus aureus, 609, 611
Streptococcus pneumoniae, 199
Statens Serum Institut, Denmark, 198
Stead, W. W., 654
Stem cell-like memory T cells, 102
Streptococcus gordonii, 611
Streptococcus parasanguinis, 611
Streptococcus pneumoniae, 199, 536
Streptomyces coelicolor, 591
streptomycin, drug resistance, 502, 503
Succinate:quinone oxidoreductase, 300–301
Swedish Institute of Infectious Disease Control, 167
Systems biology, tuberculosis, 429
TB
TB-associated immune reconstitution inflammatory syndrome (TB-IRIS), 76
T cells, see also Memory T cells
cytotoxic, in TB-immune reconstitution inflammatory syndrome (TB-IRIS), 255–256
M. tuberculosis, 217–219, 548–549
responses to tuberculosis (TB), 225
Technical Expert Group, 365
Thioalkalivibrio, 458
Thorobdovibrio, 458
Thioridazine, 297, 299
Threonine auxotroph, 704
Time-lapse microscopy, 684–685
Tissue remodeling, tuberculosis (TB), 225
toll-like receptor 9 (TLR9), 4
toll-like receptors (TLRs), 7–8, 39, 145
Trained immunity, 13, 17, 107
Transcriptional profiling, *M. tuberculosis* in macrophages, 636–638
Transcriptome studies, 674, 683–684
Transcriptomic profiling, biomarkers, 226–227
Transforming growth factor β (TGFβ), 48
Transgenic mice, 145
TrasSH screening method, 704
Treatment outcomes, impact of GeneXpert
MTB/RIF, 401, 402–404
Trifluoperazine, 299, 300
Trudeau, E. L., 131
Tryptophan auxotroph, 704–705
Tuberculin skin testing (TST), 213, 214, 215, 220, 221, 225
administering and reading TST, 381
latent TB infection, 380
purified protein derivative (PPD)-based
TST, 381
Tuberculosis (TB), *see also* Animal models;
HIV-TB coinfection; Human tuberculosis (TB); Vaccine candidates
adjunctive therapeutic vaccination, 196–197
anti-TB vaccine design, 39
biomarkers in human, 226–227
diabetes mellitus, 222–223
diversity, 680
global epidemic, 389–390
HIV-1 heterogeneity at site of disease, 247
HIV-1 replication at site of disease, 245–247
HIV and, 172, 222
lung, 3–6
malnutrition, 223–224
necrotizing lesions in active pulmonary,
533–534
positive and negative roles of chemokines
in, 36
positive and negative roles of cytokines
in, 35
post-primary, 119–121, 123–127
preventing recurrent TB, 196–197
progression of disease, 193–196
protection from infection to disease,
222–226
proposed framework for spectrum of
infection, 380
protective memory against, 96–97
risk factors for, 222
systems biology of, 429
targeting replisome for new drug
development, 595–596
Treg cell responses in human, 74–80
vaccine, 40, 43, 45, 46, 49
vaccine development strategies, 197–198
vitamin D deficiency, 223
Tuberculosis (TB) vaccination
animal models, 80
guinea pig model, 86
mouse models, 83–84
Tumor necrosis factor alpha (TNFa), 34–37
uses in TB, 35
Type I interferons (IFN-γ), tuberculosis, 224
University of Pittsburgh, 166–167, 171
University of Zaragoza and Biofabri, 202
Urine lipoarabinomannan rapid test, 366
U.S. Department of Agriculture, 139
U.S. Food and Drug Administration
(FDA), 382
Vaccine, vaccine candidate, 197, 198, 202
Vaccination
adjunctive therapeutic vaccination, 196–197
BCG and disease protection, 194
clinical trials of TB candidates, 197–203
*M. tuberculosis*, 95–96
prevention of *M. tuberculosis* infection,
193–195
prevention of recurrent TB disease,
196–197
prevention of TB disease, 195–196
Vaccine candidates, 198
Ad5Ag85A, 201
Crucell Ad35, 201
DAR-901, 202
development strategies, 197–198
eperimental medicine role in
development, 203–206
global clinical pipeline of, 198
H1:IC31 and H1:CAF01, 198
H4:IC31, 199
H56:IC31, 198–199
ID93+GLA-SE, 199
H5:IC31, 199–200
Inactivated whole-cell and fragmented TB
candidates, 202
M72/AS01E, 199–200
MVA85A, 200–201
MTBVAC, 202–203
MVA85A, 200–201
Protein-adjuvant TB vaccines, 198–200
recombinant mycobacterial vaccines,
202–203
RUTI, 202
seca2 mutant as, 619–620
TB/Flu-04L, 202
Vaccine, 202
VAP 1002, 203
viral-vectored vaccines, 200–202
VPM 1002, 203
Vaccines, *see also* Vaccine candidates
Ad85A (human adenovirus 5 expressing
Ag85A), 181–182
animal models and testing protocols,
136, 137
animal models for assessment of, 135
antibody-inducing, 220
BCG protection, 40, 43, 45, 46, 49, 220
BCG vaccination in animals, 100
BCG vaccination in guinea pigs, 86
BCG vaccination in humans, 76, 100
BCG vaccination in mice, 83–84
biomarkers correlating disease
severity, 184
biomarkers predicting efficacy, 182
guinea pig model, 153–154
macaque models of evaluating TB vaccine,
167, 170
mechanism of protection, 136
memory immunity by novel TB, 107–108
*Mycobacterium bovis* bacillus Calmette-
Guérin (BCG), 95, 117, 179–180
new-generation TB, 180–182
novel TB candidate MVA85A, 77–78, 96,
104, 108, 200–201
predictivity of animal models, 137–138
proof of concept for, 194, 196, 203–206
role of experimental medicine in vaccine
development, 203–206
schedules of BCG and virally vectored,
183–184
types of new, tested in cattle, 181
Vakzine Projekt Management GmbH, 203
Valine auxotroph, 704
Valinomycin, 297, 298
Vertex Pharmaceuticals, 643
Vibrio cholerae, 465
Viral-vectored vaccines, 200–202
Vitamin B5 (pantothenate), 706
Vitamin B7 (biotin), 707
Vitamin B9 (folate), 707
Vitamin B12 (cobalamin), 707–708
Vitamin D deficiency, 223
Wallgren, Arvid, 215
Wayne model, hypoxia, 318, 323, 325
Whole-genome sequencing (WGS)
emergence of, 495
*M. tuberculosis* L2 Beijing subslineage,
500
resistant strains, 502, 506–507
World Health Organization (WHO), 193,
226, 239
global TB epidemic, 389–390
line probe assay recommendations,
368–369
TB disease control, 379, 533
TB screening, 363, 364
X
XLAAD (X-linked autoimmune allergic
dysregulation syndrome), 73
Xpert MTB/RIF, *see also* GeneXpert
MTB/RIF technology
background of, 391
diagnostics for TB, 365, 368
maximizing impact of new diagnostics,
371, 373–374
timeline of availability, 374
Y
Yersinia pseudotuberculosis, 674
Zebrasea
animal models, 133, 685, 686
granuloma formation, 135
in *vitro* model, 530
*M. marinum*, 36, 133, 699
Ziehl, F., 520
ZN (Ziehl-Neelsen) stain, 519; *see also* AF
(acid-fast) mycobacteria
clinical diagnosis of TB, 522–523
history of acid-fast (AF) staining, 520–522
*M. tuberculosis*, 521, 528